2 completed. 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Completed 2 |
Follow CIN3: new trials by email Literature Review of CIN3 trials Research Report on CIN3
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluate the Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females Experimental: Experimental: 9-valent Human Papillomavirus (Types 6, 11, 16, 18, 31, 33, 45, 52, 58), Active Comparator: GARDASIL ®9 - HPV Infections, Cervical Cancer | Phase 3 | Completed | Shanghai Bovax Biotechnology Co., Ltd. | 1200 | 2020-09-19 | 2023-11-24 |
| Evaluate the Immunogenicity and Safety of 4-valent and 9-valent HPV Recombinant Vaccine in Chinese Healthy Females 4-valent HPV Vaccine, 9-valent HPV Vaccine, GARDASIL® - Cervical Cancer, Vulvar Cancer | Phase 3 | Completed | Shanghai Bovax Biotechnology Co., Ltd. | 1680 | 2020-05-28 | 2022-02-25 |
Condylomata Acuminata (2) · Uterine Cervical Neoplasms (2) · Vaginal Neoplasms (2) · Vulvar Neoplasms (2) · Papillomavirus Infections (1)
Communicable Diseases (2) · DNA Virus Infections (2) · Disease Attributes (2) · Female Urogenital Diseases (2) · Female Urogenital Diseases and Pregnancy Complications (2) · Genital Diseases (2) · Genital Diseases, Female (2) · Genital Neoplasms, Female (2) · Infections (2) · Neoplasms (2) · Neoplasms by Site (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Sexually Transmitted Diseases (2) · Sexually Transmitted Diseases, Viral (2)
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 (1)
Shanghai Bovax Biotechnology Co., Ltd. (2)
China (2)